• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Oncology
  • Awards
    • CRO Awards
    • Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

gene therapy

Redbrick building with Sarepta name and logo
Pharma

2nd patient dies after Sarepta's DMD gene therapy Elevidys

Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.
Angus Liu Jun 16, 2025 10:58am
bluebird

bluebird investors get on board with sale to Carlyle, SK Capital

May 30, 2025 11:50am
The Top Line

Biopharma briefing: Q1 trends, gene therapy news, ASCO preview

May 30, 2025 9:46am
Collage poster study of businessmen picture chart arrow goes up

Novartis, Sarepta tipped to drive genomic therapy sales boom

May 15, 2025 12:18pm
increase

Bluebird investor reluctance pays off with better buyout offer

May 14, 2025 10:40am
warning

Bluebird warns of potential bankruptcy amid buyout delay

May 13, 2025 9:56am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings